Glenmark Pharmaceuticals has posted a year-on-year decline in its consolidated net profit for the first quarter, attributing the drop primarily to litigation expenses related to its US operations. While the company maintained steady revenue growth driven by strong performance in domestic and select emerging markets, the impact of legal settlements and associated costs weighed on profitability. Management remains confident about the company’s long-term prospects, citing a robust product pipeline, expanding global footprint, and focus on specialty and complex generics.